\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Evaluation of the Mutagenic Potential of Orlistat in Root Merymatic Cells of Allium cepa},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2017-01-15 (revised: 15 January 2017)}
\def\TheID{\makeatother }
\def\TheDate{2017-01-15}
\title{Evaluation of the Mutagenic Potential of Orlistat in Root Merymatic Cells of Allium cepa}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{R.P.  Gomes}

             \author[2]{L.C.  Carneiro}

\renewcommand\Authands{ and }

\date{\small \em Received: 13 December 2016 Accepted: 4 January 2017 Published: 15 January 2017}

\maketitle


\begin{abstract}
        


It has been manufactured constantly, more drugs against obesity, and a great part of these medicines can be bought without prescription, as is the case of Orlistat®. However, some drugs can cause genotoxic effects in the body, which are closely related to carcinogenesis and are therefore capable of cause DNA modifications and can cause great damage to cells. In order to provide information on safety for human health, thus contributing to public health, it is hoped to increase the knowledge about the genotoxic activity of the drug. Orlistat® to provide a broader picture of the possible side effects of this drug. For this, the Allium cepa test with different concentrations of Orlistat® was performed. It was found that the drug induced chromosomal aberrations in meristematic cells of onion root. Genotoxic assessment of medicinal products increases the complexity of assessing its side effects.

\end{abstract}


\keywords{obesity, genotoxicity, weight loss.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{I. Introduction}]{I. Introduction}\par
besity is a disease characterized by dysregulated accumulation of fat in the body, which is associated with health risks due to its relationship with various metabolic complications. It is simultaneously a disease and one of the most important risk factors for other chronic non -communicable diseases, such as cardiovascular diseases and Diabetes mellitus (Pi-Sunyer et al., 1997; \hyperref[b11]{Halpern and Mancini, 1999;}\hyperref[b12]{Halpern et al., 2000;}\hyperref[b9]{Fortes et al., 2006)}.\par
For the treatment of this disease the daily insertion of pharmacological and / or nonpharmacological therapies such as physical exercises, change of eating habits, surgical procedures and medications, respectively, is recommended.\par
In an attempt to aid in the treatment of obesity, there are currently drugs with direct and / or indirect weight-loss properties such as those that inhibit appetite (catecholaminergic), which increase satiety (serotonergic), those that decrease fat absorption and those that increase burning of fat (Guyton e Hall, 1997; Pi-Sunyer, 1997; Halpern e Mancini, 1999; Radominski, 2010).\par
Among these drugs, Orlistat® is of recent use in the treatment of obesity, which has a mechanism of action different from the others because it inhibits the lipases of the gastrointestinal tract, which are responsible for the cleavage and subsequent absorption of fatty acids  {\ref (Drent e Veen, 1993;}\hyperref[b8]{Drent et al., 1995;}\hyperref[b24]{Zhi et al., 1995;} {\ref Zhi et al., 1996;}\hyperref[b13]{James et al., 1997)}.\par
Also known as tetrahydrolipostatin, it is a specific inhibitor of gastric and pancreatic lipases, which are important for aiding the digestion of fats in the diet \hyperref[b8]{(Drent et al., 1995)}. This drug is chemically synthesized from a hydrogenated derivative of the lipostatin produced by Streptomyces toxytricini (Drent e Veen , 1993; \hyperref[b23]{Zhi et al., 1994}; Amatruda e Welle, 1995). With the following structure (Fig. \hyperref[fig_0]{1}):\par
The evaluation of the carcinogenic risk / benefit ratio should always be performed before prescribing a drug \hyperref[b2]{(Brambilla et al., 2011;}\hyperref[b3]{Brambilla et al., 2012)}.\par
Therefore, this work aims to contribute to a riskbenefit projection of the use of this drug, demonstrating the possible genotoxic effects of this treatment. The objective of this study was to evaluate the mutagenic potential of Orlistat® in meristematic cells of Allium cepa; Quantify the mutagenic effects of Orlistat® in the test system used; contribute to the elucidation of information on probable adverse effects caused by the indiscriminate use of Orlistat®. 
\section[{II. Methodology}]{II. Methodology}\par
Organic onion bulbs were purchased locally with reliable source. The dry external scales were removed without damaging the root area and the central O K parenchyma of the bud crown was also removed by circular incision to increase the uptake and uniformity of budding and root growth. These bulbs were washed in running water for about 20 minutes. Carefully, the roots of the bulbs were exposed with the samples in covered glass beakers to prevent light from entering, so that only the central parenchyma of the bud crown was in contact with the samples. For each sample analyzed, five onion bulbs were used and placed in contact with the samples for 24 hours. The negative control was performed in the same manner using distilled water and ethanol in the ratio 1: 1 (solvent) \hyperref[b21]{(Rank. and Nielsen, 1993;}\hyperref[b14]{Kruger, 2009;} {\ref Cuchiar et al., 2012)}.\par
The standard orlistat test concentrations for the experiments were 60 mg/L, 360 mg/L and 500 mg/L. These concentrations were selected on the basis of the doses considered subdose (where the dose described is lower than the dose at which the drug reaches therapeutic effect), therapeutic dose (from 60 to 120mg, 3 times a day) until overdose (where the dose described is higher than the dose at which the drug achieves therapeutic effect, and may reach toxicological effect \hyperref[b24]{(Zhi et al., 1995)}. The positive control was Paracetamol® at 800 mg / L concentration.\par
After growth, the roots immersed in the samples were measured and then fixed in Carnoy's solution (acetic acid and ethyl alcohol, in the concentration of 3: 1) for 12 hours. After fixation, the roots were washed in distilled water for five minutes and stained on slides. For this, the roots were stained with acetic orcein dye in the dilution of 2\% orcein and 45\% acetic acid. The root tips were cut and heated for one minute in counting with the dye. Then, the roots were placed on slides covered by coverslips and one drop of acetic orcein dye was added between slide and cover slip. Subsequently, the root was crushed by gentle pressure. The observation of the slides was performed under an optical microscope with a 100x objective, counting 5000 cells, observing the mitotic indexes and the chromosomal and mitotic changes \hyperref[b22]{(Ribeiro and Grotzner, 2012;}\hyperref[b6]{Dias, 2014)}.\par
The calculation of the mitotic index (MI) and the index of chromosomal and mitotic aberrations (ICMA) occurred according to the following equations: MI = number of cells in mitosis x 100 ÷ total number of cells observed ICMA = number of altered cells x 100 ÷ total number of cells observed For statistical analysis, the ANOVA test was used, with significance level ? = 0.05, using the statistical package GrafPad Prism 5.0. 
\section[{III.}]{III.} 
\section[{Results}]{Results}\par
The characterization of the genotoxicity and cytotoxicity of Orlistat® was performed by root growth analysis of Allium cepa, in order to evaluate the inhibition of root growth, mitotic index (GMI) and mitotic and chromosomal abnormalities index (MCAI).\par
The results of the analysis of variance by the ANOVA test of root growth are described in Fig.  {\ref 2}. It was possible to verify that the root growth of a strain in the negative control did not present statistically significant difference of the means obtained in the roots treated with the three concentrations of the drug, so Orlistat® did not interfere with the growth of onion roots. 
\section[{Fig. 2: Root growth of Allium cepa}]{Fig. 2: Root growth of Allium cepa}\par
In relation to MI, when comparing the negative control and the treatments, in the three concentrations the drug significantly reduced the MI in the two lowest concentrations, as can be observed in Fig.  {\ref 3}. 
\section[{Fig. 3: Mitotic Index}]{Fig. 3: Mitotic Index}\par
Orlistat® significantly increased ICMA when compared to the negative control. This increase had a dose-response effect (Fig. \hyperref[fig_1]{4}).  
\section[{IV. Discussion}]{IV. Discussion}\par
In the study of \hyperref[b15]{Lopes and Vicentini (2002)} with mouse bone marrow cells, Orlistat® showed no mutagenic effect at the concentrations tested (0.2, 0.4 and 0.6 mg/mL). Concentrations tested in the above work are considerably lower than those tested in this study.\par
Based on this survey of the mutagenic potential of the Orlistat® drug in Allium cepa meristematic root cells, the number of mutations was high, as was a study with Drosophila melanogaster, in which Orlistat® was tested at the standard cross-Enzymatic basements) and improved cross-fertilization (with metabolic activation). At the standard crossing, the drug did not show genotoxic effects, but at the improved crossbreeding it was genotoxic, demonstrating that Orlistat® has an indirect genotoxic effect on D. melanogaster, suggesting that cytochrome P450 enzymes interfere with the genotoxicity of the compound. On the other hand, when co-administered with doxorubicin, Orlistat® modulated the action of this agent \hyperref[b17]{(Orsolin et al., 2012)}. Moreover,in carcinogenicity tests in Drosophila melanogaster, Orlistat® did not induce tumors, nor did it modulate the action of Mitomycin C in relation to tumor formation \hyperref[b17]{(Orsolin et al., 2012;}\hyperref[b16]{Menendez et al., 2005)}, Orlistat® showed antitumor effect in breast cancer cells. However, in another study Orlistat® showed genotoxicity in human lymphocytes in the presence of caffeine by in vitro comet assays, was induced DNA damage prior to the repair mechanism \hyperref[b4]{(Chakrabart et al., 2016)}.\par
Therefore, as genotoxicity may be related to carcinogenesis, it is necessary to monitor chronic medications to make a profile with regard to the possible side effects produced by them and thus serve as support to ensure health safety oxcf people who use these medicines. Therefore, further research should be carried out in order to broaden our understanding of the genotoxicity of Orlistat®.   \begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-2.png}
\caption{\label{fig_0}Fig. 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4}\includegraphics[]{image-3.png}
\caption{\label{fig_1}Fig. 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-4.png}
\caption{\label{fig_2}Figures}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{12}\includegraphics[]{image-5.png}
\caption{\label{fig_3}Fig. 1 :Fig. 2 :K}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{34}\includegraphics[]{image-6.png}
\caption{\label{fig_4}Fig. 3 :Fig. 4 :}\end{figure}
 			\footnote{Volume XVII Issue III Version I © 2017 Global Journals Inc. (US) Year 2017} 			\footnote{© 2017 Global Journals Inc. (US)} 			\footnote{Volume XVII Issue III Version I © 2017 Global Journals Inc. (US) Year 2017} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Baxter and Frohman]{b1}\label{b1} 	 		\textit{},  		 			J D Baxter 		,  		 			L Frohman 		.  		Mc GrawHill. 3.  	 
\bibitem[Amatruda and Welle ()]{b0}\label{b0} 	 		\textit{},  		 			J M Amatruda 		,  		 			S Welle 		.  	 	 		\textit{Endocrinology and metabolismo. Felig}  		1995.  	 
\bibitem[Halpern and Mancini ()]{b11}\label{b11} 	 		\textit{},  		 			A Halpern 		,  		 			M C Mancini 		.  	 	 		\textit{Obesidade. Jovem médico}  		1999. 1 p. .  	 
\bibitem[Rank and Nielsen ()]{b21}\label{b21} 	 		‘A modified Allium test as a tool in the screening of genotoxicity of complex mixtures’.  		 			J Rank 		,  		 			M H Nielsen 		.  	 	 		\textit{Hereditas}  		1993. 118 p. .  	 
\bibitem[James ()]{b13}\label{b13} 	 		‘A one -year trial to asses the value of orlistat in the management of obesity’.  		 			W P T James 		.  	 	 		\textit{International Journal of Obesity}  		1997. 21 p. .  	 
\bibitem[Menendez et al. ()]{b16}\label{b16} 	 		‘Antitumoral actions of the anti-obesity drug orlistat (Xenical) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu(erb B-2) oncogene’.  		 			J A Menendez 		,  		 			L Vellon 		,  		 			R Lupu 		.  	 	 		\textit{Ann. Oncol}  		2005. 16 p. .  	 
\bibitem[Kruger ()]{b14}\label{b14} 	 		\textit{Análise da toxicidade e da genotoxicidade de agrotóxicos utilizados na agricultura utilizando bioensaios com Allium cepa},  		 			R A Kruger 		.  		2009. Novo Hamburgo.  	 	 (Dissertação de Mestrado em Qualidade Ambiental -Feevale) 
\bibitem[Orsolin et al. ()]{b17}\label{b17} 	 		‘Assessment of the mutagenic, recombinagenic and carcinogenic potential of orlistat in somatic cells of Drosophila melanogaster’.  		 			P C Orsolin 		,  		 			R G Silva-Oliveira 		,  		 			J C Nepomuceno 		.  	 	 		\textit{Food and Chemical Toxicology}  		2012. 50 p. .  	 
\bibitem[Radominski ()]{b20}\label{b20} 	 		\textit{Atualização das diretrizes para o tratamento farmacológico da obesidade e do sobrepeso},  		 			R B Radominski 		.  		2010. ABESO.  	 
\bibitem[Lopes and Vicentini ()]{b15}\label{b15} 	 		\textit{Avaliação da mutagenicidade do Xenical (Orlistat) utilizando-se células da medula óssea de ratos Wistar, em tratamento agudo, via gavagem},  		 			E F Lopes 		,  		 			V E P Vicentini 		.  		2002.  		 			XI Encontro de Iniciação Científica da Universidade Estadual de Maringá 		 	 
\bibitem[Dias ()]{b6}\label{b6} 	 		\textit{Efeito genotóxico e antiproliferativo de Mikania cordifolia (LF) Willd. (Asteraceae) sobre o ciclo celular de Allium cepa L. Revista brasileira plantas medicinais},  		 			M G Dias 		.  		2014. 16 p. .  	 
\bibitem[Halpern et al. ()]{b12}\label{b12} 	 		‘Experiência clínica com o uso conjunto de Sibutramina e Orlistat em pacientes obesos’.  		 			A Halpern 		,  		 			A P Monegaglia 		,  		 			A B G Oliva 		,  		 			M Beyruti 		,  		 			Z S C Halpern 		,  		 			M C Mncini 		.  	 	 		\textit{Arq Bras Endocrinol Metab}  		2000. 44 p. .  	 
\bibitem[Chakrabart et al. ()]{b4}\label{b4} 	 		‘Genotoxicity of antiobesity drug orlista and effect of caffeine intervention: an in vitro study’.  		 			M Chakrabart 		,  		 			I Ghosh 		,  		 			A Jana 		,  		 			M Ghosh 		,  		 			A Mukherjee 		.  	 	 		\textit{Drug and Chemical Toxicology}  		2016. p. .  	 
\bibitem[Popkin ()]{b19}\label{b19} 	 		\textit{Global context of obesity. Handbook of Obesity Prevention},  		 			B M Popkin 		.  		2007. p. .  	 
\bibitem[Drent and Veen ()]{b7}\label{b7} 	 		‘Lipase inhibition: a novel concept in the treatment of obesity’.  		 			M L Drent 		,  		 			E A Veen 		.  	 	 		\textit{International Journal of Obesity and Related Metabolic Disorders}  		1993. 17 p. .  	 
\bibitem[Pi-Sunyer (ed.) ()]{b18}\label{b18} 	 		\textit{Obesity. In: Cecil tratado de medicina interna},  		 			F X Pi-Sunyer 		.  		Bennett, J.C. and Plum, F. 20 ed. Rio de Janeiro: Guanabara Koogan (ed.)  		1997. 1997.  	 
\bibitem[Drent ()]{b8}\label{b8} 	 		‘Orlistat (RO 18-0647), a lipase inhibitor , in the treatment of human obesity : a multiple dose study’.  		 			M L Drent 		.  	 	 		\textit{International Journal of Obesity}  		1995. 19 p. .  	 
\bibitem[Fortes et al. ()]{b9}\label{b9} 	 		‘Orlistat e sibutramina: bons coadjuvantes para perda e manutenção de peso?’.  		 			R C Fortes 		,  		 			N G Guimarães 		,  		 			A Haack 		,  		 			A A L Torres 		,  		 			K M B Carvalho 		.  	 	 		\textit{Rev. Bras. Nutr. Clin}  		2006. 21 p. .  	 
\bibitem[Zhi ()]{b23}\label{b23} 	 		‘Retrospective population based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers’.  		 			J Zhi 		.  	 	 		\textit{Clinical Pharmacology \& Therapeutics}  		1994. 56 p. .  	 
\bibitem[Zhi ()]{b24}\label{b24} 	 		‘Review of limited systemic absorption of orlistat , a lipase inhibitor in a healthy human volunteers’.  		 			J Zhi 		.  	 	 		\textit{J. Clin . Pharmacol}  		1995. 35 p. .  	 
\bibitem[Cuchiara et al. ()]{b5}\label{b5} 	 		‘Sistema teste de Allium cepa como bioindicador da citogenotoxicidade de cursos d'água’.  		 			C C Cuchiara 		,  		 			C S Borges 		,  		 			V L Bobrowski 		.  	 	 		\textit{Tecnologia Ciência Agropecuária}  		2012. 6 p. .  	 
\bibitem[Brambilla et al. ()]{b2}\label{b2} 	 		‘Studies on genotoxicity and carcinogenicity of antibacterial, antiviral, antimalarial and antifungal drugs’.  		 			G Brambilla 		,  		 			F Mattioli 		,  		 			L Robbiano 		,  		 			A Martelli 		.  	 	 		\textit{Mutagenesis}  		2011. p. .  	 
\bibitem[Guyton and Hall ()]{b10}\label{b10} 	 		\textit{Tratado de fisiologia médica},  		 			A C Guyton 		,  		 			J E Hall 		.  		1997. Rio de Janeiro: Guanabara Koogan. 9.  	 
\bibitem[Ribeiro et al. ()]{b22}\label{b22} 	 		‘Técnicas e Métodos para Utilização Prática de Microscopia’.  		 			C A O Ribeiro 		,  		 			H S Reis Filho 		,  		 			S R Grotzner 		.  	 	 		\textit{GEN -Grupo Editorial Nacional, Editora Santos}  		2012. 1 p. 440.  	 
\bibitem[Brambilla et al. ()]{b3}\label{b3} 	 		‘Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals’.  		 			G Brambilla 		,  		 			F Mattioli 		,  		 			L Robbiano 		,  		 			A Martelli 		.  	 	 		\textit{Mutation Research}  		2012. 750 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
